Plain-English translation of NCT05316883 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Schizophrenia research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This study is testing , a medication used when other antipsychotic drugs haven't worked well enough. Researchers want to understand which patients benefit most from this treatment by looking at blood markers and changes in the brain over 12 weeks. The goal is to eventually predict who will respond well to before starting it.
Some people with schizophrenia don't respond to standard antipsychotic medications, and this medication can be very helpful for them—but it doesn't work equally well for everyone. By finding biological markers that show who will benefit, doctors could make better treatment decisions faster.
You likely qualify if…
You likely don't qualify if…
You will take at doses adjusted to manage side effects and improve your symptoms. At the start and again after 12 weeks, you will have clinical rating assessments, blood tests to check for inflammation markers, an MRI brain scan, cognitive testing, and possibly a spinal fluid sample. The study team will monitor you closely throughout to ensure the treatment is working and side effects are manageable.
AI-generated summary from trial data · Jun 29, 2026 · Not medical advice
Denmark